Invasive candidiasis in non-hematological patients

Area of Science:

• Medical Mycology
• Infectious Diseases
• Clinical Microbiology

Background:

• Candida bloodstream infections cause significant morbidity and mortality.
• Risk factors for invasive candidiasis (IC) include immunocompromise, prolonged hospitalization, intravascular catheters, ICU stays, and chemotherapy.
• The epidemiology of IC is shifting towards non-albicans species with intrinsic or acquired antifungal resistance.

Purpose of the Study:

• To review current strategies for managing invasive candidiasis.
• To highlight the challenges posed by evolving Candida species and antifungal resistance.
• To discuss the role of early diagnosis and targeted therapy in reducing IC-related mortality.

Main Methods:

• Review of current literature on Candida bloodstream infections and invasive candidiasis.
• Analysis of epidemiological trends and antifungal resistance patterns.
• Evaluation of diagnostic and therapeutic strategies, including prophylaxis, empirical, and pre-emptive therapy.

Main Results:

• Delayed therapy for IC is associated with increased morbidity and mortality.
• Traditional culture-based diagnosis is slow and lacks sensitivity.
• Emerging non-albicans Candida species present challenges due to antifungal resistance and biofilm formation.
• Pre-emptive strategies utilizing clinical prediction rules and serological markers aim for prompt treatment initiation.

Conclusions:

• Effective management of invasive candidiasis requires prompt diagnosis and appropriate antifungal therapy.
• Pre-emptive and empirical treatment strategies can optimize antifungal use in high-risk populations.
• Further research is needed to validate the performance and cost-effectiveness of diagnostic tools for pre-emptive strategies.